Macular Telangiectasia

encelto-for-mactel

Mar 21, 2025

Neurotech’s ENCELTO Makes History as the First and Only FDA-Approved Treatment for MacTel

pharma-news-for-neurotech-capricor-celltrion

Mar 11, 2025

Neurotech’s ENCELTO Becomes First FDA-Approved Treatment for MacTel Type 2; Plus Therapeutics’ Rhenium Obisbemeda Gets FDA Orphan Status; Novo Nordisk Cuts WEGOVY to $499/Month; Capricor’s Deramiocel Wins FDA Priority Review; Celltrion’s OMLYCLO Becomes First Interchangeable XOLAIR Biosimilar

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper